Table 2.
LncRNAs in different cancers and their associated viral infections
| LncRNA name | Changes in cancer type | Virus | Refs |
|---|---|---|---|
| Enhancer of zeste homolog 2 (EZH2) | HCC | HCV | [27] |
| LINC01419 | early HCC stages | HCV | [34] |
| BC014579 | HCV | [34] | |
| BC014579 | HCV | [34] | |
| AK021443 | Increasing in late HCC | HCV | [34] |
| RP11-401P9.4 | HCV | [34] | |
| RP11-304 L19.5 | HCV | [34] | |
| AF070632 | Decrease in late stage HCC | HCV | [34] |
| CTB-167B5.2 | HCV | [34] | |
| hypoxia-inducing factor aHIF | Downregulated in HCC | HCV | [35,36] |
| Prader Willi/Angelman region RNA 5 (PAR5) | Downregulated in HCC | HCV | [35,36] |
| human downregulated expression by HBx (hDREH) | Up regulated in HCC | HCV | [35,36] |
| Hox transcript antisense intergenic RNA (HOTAIR) | Highly expressed in HCC | HCV | [38] |
| WD repeat containing antisense to TP53 (WRAP53) | Highly expressed in HCC | HBV | [43] |
| urothelial carcinoma associated 1 (UCA1) | Highly expressed in HCC | HBV | [43] |
| NR2F21 | Downregulated in NPC | EBV | [51] |
| FAM95C | Downregulated in NPC | EBV | [51] |
| LINC01106 | Downregulated in NPC | EBV | [51] |
| CH507-513H4.6 | Upregulated in NPC | EBV | [51] |
| HAP9-AS1 | Upregulated in NPC | EBV | [51] |
| CH507-513H4.3 | Upregulated in NPC | EBV | [51] |
| RP4-794H19.1 | Upregulated in NPC | EBV | [51] |
| LINC00312 (NAG7) | Downregulated in NPC | EBV | [52] |
| LOC553103 | Downregulated in NPC | EBV | [53] |
| APAF1-AS1 | Upregulated in NPC | EBV | [54] |
| AL359062 | Upregulated in NPC | EBV | [54] |
| HOTAIR | Upregulated in HNSSC | HPV | [58] |
| PROM1 | Upregulated in HNSSC | HPV | [58] |
| CCAT1 | Upregulated in HNSSC | HPV | [58] |
| MUC19 | Upregulated in HNSSC | HPV | [58] |
| DINO | Downregulated in cervical cancer | HPV | [62] |
| GAS5 | Altered in cervical caner | HPV | [63] |
| H19 | Altered in cervical caner | HPV | [63] |
| FAM83H-AS1 | Increased in cervical caner | HPV | [63] |
| CYTOR | Upregulated in various lymphomas | EBV | [46] |
| NORAD | Upregulated in various lymphomas | EBV | [46] |
| 7SL | Downregulated in Various cancers | EBV | [48] |
| H19 | Upregulated in Various cancers | EBV | [48] |
| H19-AS | Upregulated in Various cancers | EBV | [48] |
| NDM29 | Downregulated in lymphoma | EBV | [49] |
| HOXA6as | Downregulated in lymphoma | EBV | [49] |
| HAR1B | Downregulated in lymphoma | EBV | [49] |
| Tsix | Downregulated in lymphoma | EBV | [49] |
| SNHG8 | Upregulated in EBVaGC | EBV | [68] |
| RP5-1039 K5.19 | Upregulated in EBVaGC | EBV | [68] |
| TP73-AS1 | Upregulated in EBVaGC | EBV | [68] |
| MALAT1 | Upregulated in NPC | EBV | [54] |
| Upregulated in diffuse large B cell lymphoma | EBV | [56] |